10.4.3Does screening pregnant women for cytomegalovirus (CMV) infection lead to improved maternal and perinatal outcomes?

StudyRef.PopulationInterventionOutcomesResultsCommentsStudy typeEL
Bolyard et al., 1998377Repeated testing is necessary to identify CMV because it can be shed
Seroposivity does not offer complete protection against maternal reinfection and subsequent fetal infection
No currently available vaccines or prophylactic therapy
GL4
Stagno and Whitley, 1985378Maternal immunity does not prevent virus reactivation nor transmission to fetus
No effective drug therapy for CMV or its transmission exists
No ways to determine whether intrauterine transmission has occurred
No way to determine whether infected infant will have serious sequelae
RV4

From: Evidence tables

Cover of Antenatal Care
Antenatal Care: Routine Care for the Healthy Pregnant Woman.
NICE Clinical Guidelines, No. 62.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2008 Mar.
Copyright © 2008, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.